Poxel S.A.
Poxel S.A., a clinical-stage biopharmaceutical company, develops novel treatments for metabolic pathophysiology, type 2 diabetes, and liver diseases. It also develops treatments for rare metabolic diseases and associated steatohepatitis to metabolic dysfunction. The company's lead product is TWYMEEG (Imeglimin), an oral drug candidate that targets mitochondrial dysfunction and approved for the tr… Read more
Poxel S.A. (0RA2) - Total Liabilities
Latest total liabilities as of June 2025: €66.41 Million EUR
Based on the latest financial reports, Poxel S.A. (0RA2) has total liabilities worth €66.41 Million EUR as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Poxel S.A. - Total Liabilities Trend (2010–2024)
This chart illustrates how Poxel S.A.'s total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Poxel S.A. Competitors by Total Liabilities
The table below lists competitors of Poxel S.A. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Agripure Holdings Public Company Limited
BK:APURE
|
Thailand | ฿512.45 Million |
|
Kavango Resources Plc
PINK:KVGOF
|
USA | $938.67K |
|
Cocrystal Pharma Inc
NASDAQ:COCP
|
USA | $2.78 Million |
|
Aurora Labs Ltd
AU:A3D
|
Australia | AU$1.84 Million |
|
Huayi Tencent Entertainment Company Limited
PINK:HUYTF
|
USA | $433.27 Million |
|
FSBM Holdings Bhd
KLSE:9377
|
Malaysia | RM5.53 Million |
Liability Composition Analysis (2010–2024)
This chart breaks down Poxel S.A.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.26 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.08 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 13.28 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Poxel S.A.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Poxel S.A. (2010–2024)
The table below shows the annual total liabilities of Poxel S.A. from 2010 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | €73.87 Million | +37.04% |
| 2023-12-31 | €53.90 Million | +1.79% |
| 2022-12-31 | €52.95 Million | +13.44% |
| 2021-12-31 | €46.68 Million | +22.21% |
| 2020-12-31 | €38.20 Million | +15.19% |
| 2019-12-31 | €33.16 Million | -33.33% |
| 2018-12-31 | €49.73 Million | +4.87% |
| 2017-12-31 | €47.43 Million | +334.37% |
| 2016-12-31 | €10.92 Million | +23.79% |
| 2015-12-31 | €8.82 Million | -46.13% |
| 2014-12-31 | €16.37 Million | -49.27% |
| 2013-12-31 | €32.28 Million | +310.22% |
| 2012-12-31 | €7.87 Million | +178.30% |
| 2011-12-31 | €2.83 Million | +33.66% |
| 2010-12-31 | €2.12 Million | -- |